Despite advances in early detection as described in part 1 of this continuing medical education series, melanoma continues to be a large contributor to cutaneous cancer-related mortality. In a subset of patients with unresectable or metastatic disease, surgical clearance is often not possible; therefore, systemic and local therapies are considered. The second article in this series provides dermatologists with an up-to-date working knowledge of the treatment options that may be prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaad.2021.09.075 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!